EU/3/05/333

Table of contents

About

On 14 December 2005, orphan designation (EU/3/05/333) was granted by the European Commission to DKA Consult ApS, Denmark, for eptacog alpha (activated) for the treatment of diffuse alveolar haemorrhage.

The sponsorship was transferred to Pharmaorigin ApS, Denmark, in May 2007. The sponsorship was transferred to Savara ApS, Denmark  in September 2016. The sponsor’s address was updated in November 2019.

Key facts

Active substance
eptacog alfa (activated)
Disease / condition
Treatment of diffuse alveolar haemorrhage
Date of first decision
14/12/2005
Outcome
Positive
EU designation number
EU/3/05/333

Sponsor's contact details

Savara ApS
Slotsmarken 17, 1. Th
2970 Hoersholm
Hovedstaden
Denmark
Tel: +45 7930 1417
E-mail: info@savarapharma.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating